After Apellis deal, Biogen looks to fill early-stage pipeline

Biogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we're going to be focusing on is early-stage development and research, because that part ...